0001203311-23-000078.txt : 20230817
0001203311-23-000078.hdr.sgml : 20230817
20230817205946
ACCESSION NUMBER: 0001203311-23-000078
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230815
FILED AS OF DATE: 20230817
DATE AS OF CHANGE: 20230817
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DANSEY ROGER D
CENTRAL INDEX KEY: 0001741836
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-32405
FILM NUMBER: 231183614
MAIL ADDRESS:
STREET 1: 21823 30TH DRIVE SE
CITY: BOTHELL
STATE: WA
ZIP: 98021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seagen Inc.
CENTRAL INDEX KEY: 0001060736
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 911874389
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21823 30TH DRIVE SE
STREET 2: SUITE
CITY: BOTHELL
STATE: WA
ZIP: 98021
BUSINESS PHONE: 4255274000
MAIL ADDRESS:
STREET 1: 21823 30TH DRIVE SE
STREET 2: SUITE
CITY: BOTHELL
STATE: WA
ZIP: 98021
FORMER COMPANY:
FORMER CONFORMED NAME: SEATTLE GENETICS INC /WA
DATE OF NAME CHANGE: 20001116
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2023-08-15
0
0001060736
Seagen Inc.
SGEN
0001741836
DANSEY ROGER D
21823 30TH DRIVE SE
BOTHELL
WA
98021
0
1
0
0
President, R&D & CMO
1
Common Stock
2023-08-15
4
A
0
25747
0.0
A
125193
D
Common Stock
2023-08-16
4
D
0
1804
193.8689
D
123389
D
Common Stock
2023-08-16
4
D
0
6100
193.8689
D
117289
D
Common Stock
2023-08-16
4
D
0
2348
193.8689
D
114941
D
These shares represent restricted stock units and will be settled in common stock upon vesting. 50% of the reporting person's annual equity award was granted in the form of performance stock units, which are not reflected here, and will be treated the same as these restricted stock units in the event the transaction with Pfizer
closes.
Shares shall vest at a rate of 25% on each anniversary of August 15, 2023 until all shares are fully vested at the end of four years.
Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 57 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on July 31, 2023.
The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/13/2020 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
The sales reported in this Form 4 were effected pursuant to a written plan adopted on 9/8/2022 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/4/2021 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
By: /s/ Jessica Nielsen Causey For: Roger D. Dansey
2023-08-17